共 50 条
Small molecule therapeutics targeting F-box proteins in cancer
被引:22
|作者:
Liu, Yuan
[1
]
Mallampalli, Rama K.
[1
,2
]
机构:
[1] Univ Pittsburgh, Ctr Excellence, Acute Lung Injury, Dept Med, Pittsburgh, PA 15213 USA
[2] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA
基金:
美国国家卫生研究院;
关键词:
Ubiquitin;
E3;
ligase;
F-box protein;
Small molecule inhibitor;
Cancer;
SCF UBIQUITIN-LIGASE;
NF-KAPPA-B;
CELL-CYCLE ARREST;
PHOSPHORYLATION-DEPENDENT UBIQUITINATION;
ANAPHASE PROMOTING COMPLEX/CYCLOSOME;
TUMOR-SUPPRESSOR;
BETA-TRCP;
C-MYC;
MEDIATED DEGRADATION;
PROTEASOMAL DEGRADATION;
D O I:
10.1016/j.semcancer.2015.09.014
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The ubiquitin proteasome system (UPS) plays vital roles in maintaining protein equilibrium mainly through proteolytic degradation of targeted substrates. The archetypical SCF ubiquitin E3 ligase complex contains a substrate recognition subunit F-box protein that recruits substrates to the catalytic ligase core for its polyubiquitylation and subsequent proteasomal degradation. Several well-characterized F-box proteins have been demonstrated that are tightly linked to neoplasia. There is mounting information characterizing F-box protein-substrate interactions with the rationale to develop unique therapeutics for cancer treatment. Here we review that how F-box proteins function in cancer and summarize potential small molecule inhibitors for cancer therapy. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:105 / 119
页数:15
相关论文